Oleandrin targeting Akt has been studied in preclinical settings in a wide assay of Pancreatic cancer cell lines [70] and with PDAC patients in phase I study, it showed reasonable tolerability [54,71]. Here, AKT1 is linked to familial pancreatic carcinoma.